Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Sara Zanivan Image

      Sara Zanivan, PHD

      Department of Experimental Therapeutics, Division of Cancer Medicine

      Present Title & Affiliation

      Primary Appointment

      Associate Professor, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Scientific Director Proteomics Core Facility, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Dual/Joint/Adjunct Appointment

      Honorary Professor, School of Cancer Sciences, University of Glasgow

      Research Interests

      The research of my group aims to understand the molecular mechanisms that underpin how cancer associated fibroblasts (CAFs) influence cancer pathology through interacting with other cell types and by modifying the tumour microenvironment. A major focus of our research is cell metabolism and how we can modulate it in CAFs to create an anti-tumour microenvironment and new vulnerabilities for anti-cancer therapies. The overarching goal of our research is to find ways to target CAFs to treat cancer patients effectively. My group also develops mass spectrometry (MS) proteomic approaches for cancer research. Recently, we have developed a line of clinical research aimed at the discovery of circulating biomarkers for early detection and to predict risk of cancer.


      Education & Training

      Degree-Granting Education

      2006University of Torino, Candiolo Cancer Institute IRCCS, Candiolo, Torino, IT, Complex Systems Applied to Post-Genomic Biology, Ph.D
      2002University of Torino, Candiolo Cancer Institute IRCCS, Candiolo, Torino, IT, Bioinformatics, Masters
      2001University of Torino, Candiolo Cancer Institute IRCCS, Candiolo, Torino, IT, Biology, Masters

      Postgraduate Training

      2007-2010Postdoctoral Fellow, Max-Planck Institute for Biochemistry, Martinsried
      2006-2007Postgraduate Fellow, University of Torino, Candiolo Cancer Institute IRCCS, Torino
      2002-2006Ph.D. Student, University of Torino, Candiolo Cancer Insitute IRCCS

      Experience & Service

      Editorial Activities

      Reviewer, Nature Cell Biology

      Reviewer, Matrix biology : journal of the International Society for Matrix Biology

      Reviewer, Nature reviews. Cancer

      Reviewer, Cell reports

      Reviewer, Nature Cancer

      Reviewer, Nature Metabolism

      Honors & Awards

      2023 - 2024Elected Lecturer for the British Society Proteome Research (BSPR)
      2019CRUK Conference and Meeting Award for BSPR meeting, Cancer Research UK
      2016CRUK Conference and Meeting Award for BSPR meeting, Cancer Research UK
      2012CRUK Conference and Meeting Award for EuPA meeting, Cancer Research UK
      2011Emerging Investigator by the EMBO Cancer Proteomics

      Grant & Contract Support

      Date: 2025 - 2027
      Title:High resolution molecular profiling platform to investigate the role of tumour microbiota in anti-tumour immunity
      Funding Source:University of Glasgow
      Role:Co-I
      ID:MR/Z50628X/1
      Date: 2022 - 2026
      Title:Combining plasma redox-proteomics with machine learning for early detection of hepatocellular carcinoma
      Funding Source:Cancer Reasearch UK Early Detection Project
      Role:PI
      ID:EDDPJT-Nov21\100006
      Date: 2022 - 2025
      Title:Investigating Biomarkers for the Early Detection of Pancreatic Cancer in Genetically Engineered Mouse Models of New Onset Diabetes-Associated Ductal Adenocarcinoma
      Funding Source:Cancer Research UK Early Detection Project
      Role:Co-PI
      ID:EDDPJT-Nov21\100006
      Date: 2022 - 2025
      Title:Differential Expression of Bystander Transcriptomes for Mesothelioma Diagnosis: DEBiT-Meso
      Funding Source:British Lung Foundation
      Role:Co-I
      ID:MEDPG21F\5

      Selected Publications

      Peer-Reviewed Articles

      1. Kanellos, G, Giacomelli, C, Raven, A, Vlahov, N, Jin, H, Herviou, P, Malla, SB, Nasreddin, N, Centeno, PP, Alexandrou, C, Gilroy, K, Baird, RL, Pennel, K, Munro, J, Waldron, JA, Hall, H, Officer-Jones, L, Bryson, S, Strathdee, D, Lilla, S, Zanivan, SR, Morrison, V, Nixon, C, Ridgway, RA, Miller, CJ, Knight, JR, Campbell, A, Dunne, PD, Le Quesne, J, Edwards, J, Park, PJ, Bushell, M, Sansom, OJ. Nucleophosmin supports WNT-driven hyperproliferation and tumor initiation. Nature Genetics 58(1):100-115, 2026. e-Pub 2026. PMID: 41413654.
      2. Lilla S, Atkinson S, Radau S, Bailey UM, Deshmukh AS, van der Reest J, Kirkpatrick J, MacVicar T, Zanivan S. SICyLIA-cTMT dissects redox proteome dynamics with high accuracy and depth at microgram scale. Cell Rep Methods 5(11):101210, 2025. e-Pub 2025. PMID: 41167197.
      3. Dias MM, King MS, Shokry E, Lilla S, Paul N, Thomason P, Zanivan S, Sumpton D, Kunji ERS, MacVicar T. SLC25A45 is required for mitochondrial uptake of methylated amino acids and de novo carnitine biosynthesis. Mol Cell 85(21):4093-4104.e8, 2025. e-Pub 2025. PMID: 41075794.
      4. Boscenco, S, Tait-Mulder, J, Kim, M, Tang, C, Park, T, McNulty, F, Lilla, S, Zanivan, SR, Huerta-Uribe, A, Nalbant, B, Zucker, M, Sumpton, D, Monteuuis, G, Jackson, CB, Wei, W, Chinnery, PF, Chaligné, R, Lareau, CA, Reznik, E, Gammage, PA. Functionally dominant hotspot mutations of mitochondrial ribosomal RNA genes in cancer. Nature Genetics 57(11):2705-2714, 2025. e-Pub 2025. PMID: 41184543.
      5. Whitelaw, JA, Ghosh, S, Lilla, S, Nikolaou, S, Tweedy, L, Fort, L, Paul, NR, Zanivan, SR, Gadegaard, N, Insall, RH, Machesky, LM. CYRI-B loss promotes enlarged mature focal adhesions and restricts microtubule and ERC1 access to the cell leading edge. Journal of cell science 138(22), 2025. e-Pub 2025. PMID: 41277545.
      6. Cianfanelli V, Nanni M, Corra S, Mauri S, Sumpton D, Lilla S, De Cegli R, Bordi M, Milletti G, Ferraina C, Hall A, Petraroia M, Clausi V, Giorda E, Scarsella M, Barbiera A, Cadeddu G, Colasanti M, Persichini T, Maeda K, Maya-Mendoza A, Bartek J, Di Malta C, Locatelli F, Zanivan S, Ismail S, Ziviani E, Cecconi F. The PP2A-B55alpha phosphatase is a master regulator of mitochondrial degradation and biogenesis. Sci Adv 11(40):eadw7376, 2025. e-Pub 2025. PMID: 41042873.
      7. Ahmed, SF, Anand, J, Zhang, W, Buetow, L, Rishi, L, Mitchell, L, Bohlen, J, Lilla, S, Sibbet, GJ, Nixon, C, Patel, A, Majorek, KA, Zanivan, SR, Bustamante, J, Sidhu, SS, Blyth, K, Huang, DT. Locking CBL TKBD in its native conformation presents a novel therapeutic opportunity in mutant CBL-dependent leukemia. Molecular Therapy 33(8):3624-3643, 2025. e-Pub 2025. PMID: 40329529.
      8. Gounis M, Campos AV, Shokry E, Mitchell L, Deshmukh R, Dornier E, Rooney N, Dhayade S, Pardo L, Moore M, Novo D, Mowat J, Jamieson C, Kay E, Zanivan S, Paul NR, Mitchell C, Nixon C, Macpherson I, Tardito S, Sumpton D, Blyth K, Norman JC, Clarke CJ. Metabolic adaptations of micrometastases alter EV production to generate invasive microenvironments. J Cell Biol 224(8), 2025. e-Pub 2025. PMID: 40488669.
      9. Villari, G, Gioelli, N, Gino, M, Zhang, H, Hodge, K, Cordero, F, Zanivan, SR, Zhu, J, Serini, G. Luminescent sensing of conformational integrin activation in living cells. Cell Reports 44(2), 2025. e-Pub 2025. PMID: 39964812.
      10. Luo, X, Grande Kugeratski, F, Dowlatshahi, DP, Sugimoto, H, Arian, KA, Fan, Y, Huang, L, Wills, D, Lilla, S, Hodge, K, Zanivan, SR, LeBleu, V, McAndrews, KM, Kalluri, R. Engineered Immunomodulatory Extracellular Vesicles from Epithelial Cells with the Capacity for Stimulation of Innate and Adaptive Immunity in Cancer and Autoimmunity. ACS Nano 19(5):5193-5216, 2025. e-Pub 2025. PMID: 39869047.
      11. Singh SP, Smyth DJ, Cunningham KT, Mukundan A, Byeon CH, Hinck CS, White MPJ, Ciancia C, Wasowska N, Sanders A, Jin R, White RF, Lilla S, Zanivan S, Schoenherr C, Inman GJ, van Dinther M, Ten Dijke P, Hinck AP, Maizels RM. The TGF-beta mimic TGM4 achieves cell specificity through combinatorial surface co-receptor binding. EMBO Rep 26(1):218-244, 2024. e-Pub 2024. PMID: 39609640.
      12. Ackermann T, Shokry E, Deshmukh R, Anand J, Galbraith LCA, Mitchell L, Rodriguez-Blanco G, Villar VH, Sterken BA, Nixon C, Zanivan S, Blyth K, Sumpton D, Tardito S. Breast cancer secretes anti-ferroptotic MUFAs and depends on selenoprotein synthesis for metastasis. EMBO Mol Med 16(11):2749-2774, 2024. e-Pub 2024. PMID: 39433871.
      13. Mahmood M, Liu EM, Shergold AL, Tolla E, Tait-Mulder J, Huerta-Uribe A, Shokry E, Young AL, Lilla S, Kim M, Park T, Boscenco S, Manchon JL, Rodriguez-Antona C, Walters RC, Springett RJ, Blaza JN, Mitchell L, Blyth K, Zanivan S, Sumpton D, Roberts EW, Reznik E, Gammage PA. Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma. Nat Cancer 5(4):659-672, 2024. e-Pub 2024. PMID: 38286828.
      14. Sanchez-Lopez I, Orantos-Aguilera Y, Pozo-Guisado E, Alvarez-Barrientos A, Lilla S, Zanivan S, Lachaud C, Martin-Romero FJ. STIM1 translocation to the nucleus protects cells from DNA damage. Nucleic Acids Res 52(5):2389-2415, 2024. e-Pub 2024. PMID: 38224453.
      15. Santi A, Kay EJ, Neilson LJ, McGarry L, Lilla S, Mullin M, Paul NR, Fercoq F, Koulouras G, Rodriguez Blanco G, Athineos D, Mason S, Hughes M, Thomson G, Kieffer Y, Nixon C, Blyth K, Mechta-Grigoriou F, Carlin LM, Zanivan S. Cancer-associated fibroblasts produce matrix-bound vesicles that influence endothelial cell function. Sci Signal 17(827):eade0580, 2024. e-Pub 2024. PMID: 38470957.
      16. Vringer E, Heilig R, Riley JS, Black A, Cloix C, Skalka G, Montes-Gomez AE, Aguado A, Lilla S, Walczak H, Gyrd-Hansen M, Murphy DJ, Huang DT, Zanivan S, Tait SW. Mitochondrial outer membrane integrity regulates a ubiquitin-dependent and NF-kappaB-mediated inflammatory response. EMBO J 43(6):904-930, 2024. e-Pub 2024. PMID: 38337057.
      17. Dawson A, Zarou MM, Prasad B, Bittencourt-Silvestre J, Zerbst D, Himonas E, Hsieh YC, van Loon I, Blanco GR, Ianniciello A, Kerekes Z, Krishnan V, Agarwal P, Almasoudi H, McCluskey L, Hopcroft LEM, Scott MT, Baquero P, Dunn K, Vetrie D, Copland M, Bhatia R, Coffelt SB, Tiong OS, Wheadon H, Zanivan S, Kirschner K, Helgason GV. Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche. Nat Commun 15(1):1090, 2024. e-Pub 2024. PMID: 38316788.
      18. Neilson LJ, Cartwright D, Risteli M, Jokinen EM, McGarry L, Sandvik T, Nikolatou K, Hodge K, Atkinson S, Vias M, Kay EJ, Brenton JD, Carlin LM, Bryant DM, Salo T, Zanivan S. Omentum-derived matrix enables the study of metastatic ovarian cancer and stromal cell functions in a physiologically relevant environment. Matrix Biol Plus 19-20:100136, 2023. e-Pub 2023. PMID: 38223308.
      19. Nikolatou K, Sandilands E, Roman-Fernandez A, Cumming EM, Freckmann E, Lilla S, Buetow L, McGarry L, Neilson M, Shaw R, Strachan D, Miller C, Huang DT, McNeish IA, Norman JC, Zanivan S, Bryant DM. PTEN deficiency exposes a requirement for an ARF GTPase module for integrin-dependent invasion in ovarian cancer. EMBO J 42(18):e113987, 2023. e-Pub 2023. PMID: 37577760.
      20. Subramaniam G, Schleicher K, Kovanich D, Zerio A, Folkmanaite M, Chao YC, Surdo NC, Koschinski A, Hu J, Scholten A, Heck AJR, Ercu M, Sholokh A, Park KC, Klussmann E, Meraviglia V, Bellin M, Zanivan S, Hester S, Mohammed S, Zaccolo M. Integrated Proteomics Unveils Nuclear PDE3A2 as a Regulator of Cardiac Myocyte Hypertrophy. Circ Res 132(7):828-848, 2023. e-Pub 2023. PMID: 36883446.
      21. Altea-Manzano P, Doglioni G, Liu Y, Cuadros AM, Nolan E, Fernandez-Garcia J, Wu Q, Planque M, Laue KJ, Cidre-Aranaz F, Liu XZ, Marin-Bejar O, Van Elsen J, Vermeire I, Broekaert D, Demeyer S, Spotbeen X, Idkowiak J, Montagne A, Demicco M, Alkan HF, Rabas N, Riera-Domingo C, Richard F, Geukens T, De Schepper M, Leduc S, Hatse S, Lambrechts Y, Kay EJ, Lilla S, Alekseenko A, Geldhof V, Boeckx B, de la Calle Arregui C, Floris G, Swinnen JV, Marine JC, Lambrechts D, Pelechano V, Mazzone M, Zanivan S, Cools J, Wildiers H, Baud V, Grunewald TGP, Ben-David U, Desmedt C, Malanchi I, Fendt SM. A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-kappaB signaling. Nat Cancer 4(3):344-364, 2023. e-Pub 2023. PMID: 36732635.
      22. Schmidt T, Dabrowska A, Waldron JA, Hodge K, Koulouras G, Gabrielsen M, Munro J, Tack DC, Harris G, McGhee E, Scott D, Carlin LM, Huang D, Le Quesne J, Zanivan S, Wilczynska A, Bushell M. eIF4A1-dependent mRNAs employ purine-rich 5'UTR sequences to activate localised eIF4A1-unwinding through eIF4A1-multimerisation to facilitate translation. Nucleic Acids Res 51(4):1859-1879, 2023. e-Pub 2023. PMID: 36727461.
      23. Roman-Fernandez A, Mansour MA, Kugeratski FG, Anand J, Sandilands E, Galbraith L, Rakovic K, Freckmann EC, Cumming EM, Park J, Nikolatou K, Lilla S, Shaw R, Strachan D, Mason S, Patel R, McGarry L, Katoch A, Campbell KJ, Nixon C, Miller CJ, Leung HY, Le Quesne J, Norman JC, Zanivan S, Blyth K, Bryant DM. Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function. Sci Adv 9(5):eabq1858, 2023. e-Pub 2023. PMID: 36735782.
      24. McGarry DJ, Castino G, Lilla S, Carnet A, Kelly L, Micovic K, Zanivan S, Olson MF. MICAL1 activation by PAK1 mediates actin filament disassembly. Cell Rep 41(1):111442, 2022. e-Pub 2022. PMID: 36198272.
      25. Gioelli N, Neilson LJ, Wei N, Villari G, Chen W, Kuhle B, Ehling M, Maione F, Willox S, Brundu S, Avanzato D, Koulouras G, Mazzone M, Giraudo E, Yang XL, Valdembri D, Zanivan S, Serini G. Neuropilin 1 and its inhibitory ligand mini-tryptophanyl-tRNA synthetase inversely regulate VE-cadherin turnover and vascular permeability. Nat Commun 13(1):4188, 2022. e-Pub 2022. PMID: 35858913.
      26. Baudot AD, Wang VM, Leach JD, O'Prey J, Long JS, Paulus-Hock V, Lilla S, Thomson DM, Greenhorn J, Ghaffar F, Nixon C, Helfrich MH, Strathdee D, Pratt J, Marchesi F, Zanivan S, Ryan KM. Glycan degradation promotes macroautophagy. Proc Natl Acad Sci U S A 119(26):e2111506119, 2022. e-Pub 2022. PMID: 35737835.
      27. Narva E, Taskinen ME, Lilla S, Isomursu A, Pietila M, Weltner J, Isola J, Sihto H, Joensuu H, Zanivan S, Norman J, Ivaska J. MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels. iScience 25(6):104459, 2022. e-Pub 2022. PMID: 35677646.
      28. Kay EJ, Paterson K, Riera-Domingo C, Sumpton D, Dabritz JHM, Tardito S, Boldrini C, Hernandez-Fernaud JR, Athineos D, Dhayade S, Stepanova E, Gjerga E, Neilson LJ, Lilla S, Hedley A, Koulouras G, McGregor G, Jamieson C, Johnson RM, Park M, Kirschner K, Miller C, Kamphorst JJ, Loayza-Puch F, Saez-Rodriguez J, Mazzone M, Blyth K, Zagnoni M, Zanivan S. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. Nat Metab 4(6):693-710, 2022. e-Pub 2022. PMID: 35760868.
      29. Salji MJ, Blomme A, Dabritz JHM, Repiscak P, Lilla S, Patel R, Sumpton D, van den Broek NJF, Daly R, Zanivan S, Leung HY. Multi-omics & pathway analysis identify potential roles for tumor N-acetyl aspartate accumulation in murine models of castration-resistant prostate cancer. iScience 25(4):104056, 2022. e-Pub 2022. PMID: 35345457.
      30. Blomme A, Peter C, Mui E, Rodriguez Blanco G, An N, Mason LM, Jamieson LE, McGregor GH, Lilla S, Ntala C, Patel R, Thiry M, Kung SHY, Leclercq M, Ford CA, Rushworth LK, McGarry DJ, Mason S, Repiscak P, Nixon C, Salji MJ, Markert E, MacKay GM, Kamphorst JJ, Graham D, Faulds K, Fazli L, Gleave ME, Avezov E, Edwards J, Yin H, Sumpton D, Blyth K, Close P, Murphy DJ, Zanivan S, Leung HY. THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Mol Med 14(3):e14764, 2022. e-Pub 2022. PMID: 35014179.
      31. Marco S, Neilson M, Moore M, Perez-Garcia A, Hall H, Mitchell L, Lilla S, Blanco GR, Hedley A, Zanivan S, Norman JC. Nuclear-capture of endosomes depletes nuclear G-actin to promote SRF/MRTF activation and cancer cell invasion. Nat Commun 12(1):6829, 2021. e-Pub 2021. PMID: 34819513.
      32. Gillen SL, Giacomelli C, Hodge K, Zanivan S, Bushell M, Wilczynska A. Differential regulation of mRNA fate by the human Ccr4-Not complex is driven by coding sequence composition and mRNA localization. Genome Biol 22(1):284, 2021. e-Pub 2021. PMID: 34615539.
      33. Martinez RS, Salji MJ, Rushworth L, Ntala C, Rodriguez Blanco G, Hedley A, Clark W, Peixoto P, Hervouet E, Renaude E, Kung SHY, Galbraith LCA, Nixon C, Lilla S, MacKay GM, Fazli L, Gaughan L, Sumpton D, Gleave ME, Zanivan S, Blomme A, Leung HY. SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer. Cancer Res 81(13):3664-3678, 2021. e-Pub 2021. PMID: 33985973.
      34. Kugeratski FG, Hodge K, Lilla S, McAndrews KM, Zhou X, Hwang RF, Zanivan S, Kalluri R. Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. Nat Cell Biol 23(6):631-641, 2021. e-Pub 2021. PMID: 34108659.
      35. Budden T, Gaudy-Marqueste C, Porter A, Kay E, Gurung S, Earnshaw CH, Roeck K, Craig S, Traves V, Krutmann J, Muller P, Motta L, Zanivan S, Malliri A, Furney SJ, Nagore E, Viros A. Ultraviolet light-induced collagen degradation inhibits melanoma invasion. Nat Commun 12(1):2742, 2021. e-Pub 2021. PMID: 33980846.
      36. Nacke M, Sandilands E, Nikolatou K, Roman-Fernandez A, Mason S, Patel R, Lilla S, Yelland T, Galbraith LCA, Freckmann EC, McGarry L, Morton JP, Shanks E, Leung HY, Markert E, Ismail S, Zanivan S, Blyth K, Bryant DM. An ARF GTPase module promoting invasion and metastasis through regulating phosphoinositide metabolism. Nat Commun 12(1):1623, 2021. e-Pub 2021. PMID: 33712589.
      37. Ahmed SF, Buetow L, Gabrielsen M, Lilla S, Sibbet GJ, Sumpton D, Zanivan S, Hedley A, Clark W, Huang DT. E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis. Oncogene 40(12):2149-2164, 2021. e-Pub 2021. PMID: 33627783.
      38. Phatak V, von Grabowiecki Y, Janus J, Officer L, Behan C, Aschauer L, Pinon L, Mackay H, Zanivan S, Norman JC, Kelly M, Le Quesne J, Muller PAJ. Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane. Cell Death Dis 12(2):207, 2021. e-Pub 2021. PMID: 33627632.
      39. Kilonsky DJ, Abdel Aziz, AK, Abdelfatah, S, Abdoli A, Abel S, Zanivan S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th Edition). Autophagy 17(1):1-382, 2021. PMID: 33634751.
      40. Unbekandt M, Lilla S, Zanivan S, Olson MF. The CDC42 effector protein MRCKbeta autophosphorylates on Threonine 1108. Small GTPases 11(6):451-460, 2020. e-Pub 2020. PMID: 30667325.
      41. Lobo MJ, Reverte-Salisa L, Chao YC, Koschinski A, Gesellchen F, Subramaniam G, Jiang H, Pace S, Larcom N, Paolocci E, Pfeifer A, Zanivan S, Zaccolo M. Phosphodiesterase 2A2 regulates mitochondria clearance through Parkin-dependent mitophagy. Commun Biol 3(1):596, 2020. e-Pub 2020. PMID: 33087821.
      42. Ahmed SF, Buetow L, Gabrielsen M, Lilla S, Chatrin C, Sibbet GJ, Zanivan S, Huang DT. DELTEX2 C-terminal domain recognizes and recruits ADP-ribosylated proteins for ubiquitination. Sci Adv 6(34), 2020. e-Pub 2020. PMID: 32937373.
      43. Taskinen ME, Narva E, Conway JRW, Hinojosa LS, Lilla S, Mai A, De Franceschi N, Elo LL, Grosse R, Zanivan S, Norman JC, Ivaska J. MASTL promotes cell contractility and motility through kinase-independent signaling. J Cell Biol 219(6), 2020. e-Pub 2020. PMID: 32311005.
      44. Blomme A, Ford CA, Mui E, Patel R, Ntala C, Jamieson LE, Planque M, McGregor GH, Peixoto P, Hervouet E, Nixon C, Salji M, Gaughan L, Markert E, Repiscak P, Sumpton D, Blanco GR, Lilla S, Kamphorst JJ, Graham D, Faulds K, MacKay GM, Fendt SM, Zanivan S, Leung HY. 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nat Commun 11(1):2508, 2020. e-Pub 2020. PMID: 32427840.
      45. Oizel K, Tait-Mulder J, Fernandez-de-Cossio-Diaz J, Pietzke M, Brunton H, Lilla S, Dhayade S, Athineos D, Blanco GR, Sumpton D, Mackay GM, Blyth K, Zanivan SR, Meiser J, Vazquez A. Formate induces a metabolic switch in nucleotide and energy metabolism. Cell Death Dis 11(5):310, 2020. e-Pub 2020. PMID: 32366892.
      46. Cao X, Lilla S, Cao Z, Pringle MA, Oka OBV, Robinson PJ, Szmaja T, van Lith M, Zanivan S, Bulleid NJ. The mammalian cytosolic thioredoxin reductase pathway acts via a membrane protein to reduce ER-localised proteins. J Cell Sci 133(8), 2020. e-Pub 2020. PMID: 32184267.
      47. Loveridge CJ, Slater S, Campbell KJ, Nam NA, Knight J, Ahmad I, Hedley A, Lilla S, Repiscak P, Patel R, Salji M, Fleming J, Mitchell L, Nixon C, Strathdee D, Neilson M, Ntala C, Bryson S, Zanivan S, Edwards J, Robson CN, Goodyear CS, Blyth K, Leung HY. BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene 39(8):1797-1806, 2020. e-Pub 2020. PMID: 31740786.
      48. Tait-Mulder J, Hodge K, Sumpton D, Zanivan S, Vazquez A. The conversion of formate into purines stimulates mTORC1 leading to CAD-dependent activation of pyrimidine synthesis. Cancer Metab 8:20, 2020. e-Pub 2020. PMID: 32974014.
      49. Wilczynska A, Gillen SL, Schmidt T, Meijer HA, Jukes-Jones R, Langlais C, Kopra K, Lu WT, Godfrey JD, Hawley BR, Hodge K, Zanivan S, Cain K, Le Quesne J, Bushell M. eIF4A2 drives repression of translation at initiation by Ccr4-Not through purine-rich motifs in the 5'UTR. Genome Biol 20(1):262, 2019. e-Pub 2019. PMID: 31791371.
      50. Ferraro DA, Patella F, Zanivan S, Donato C, Aceto N, Giannotta M, Dejana E, Diepenbruck M, Christofori G, Buess M. Endothelial cell-derived nidogen-1 inhibits migration of SK-BR-3 breast cancer cells. BMC Cancer 19(1):312, 2019. e-Pub 2019. PMID: 30947697.
      51. Kugeratski FG, Atkinson SJ, Neilson LJ, Lilla S, Knight JRP, Serneels J, Juin A, Ismail S, Bryant DM, Markert EK, Machesky LM, Mazzone M, Sansom OJ, Zanivan S. Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. Sci Signal 12(567), 2019. e-Pub 2019. PMID: 30723174.
      52. Whitelaw JA, Lilla S, Paul NR, Fort L, Zanivan S, Machesky LM. CYRI/ Fam49 Proteins Represent a New Class of Rac1 Interactors. Commun Integr Biol 12(1):112-118, 2019. e-Pub 2019. PMID: 31413787.
      53. Novo D, Heath N, Mitchell L, Caligiuri G, MacFarlane A, Reijmer D, Charlton L, Knight J, Calka M, McGhee E, Dornier E, Sumpton D, Mason S, Echard A, Klinkert K, Secklehner J, Kruiswijk F, Vousden K, Macpherson IR, Blyth K, Bailey P, Yin H, Carlin LM, Morton J, Zanivan S, Norman JC. Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nat Commun 9(1):5069, 2018. e-Pub 2018. PMID: 30498210.
      54. Fort L, Batista JM, Thomason PA, Spence HJ, Whitelaw JA, Tweedy L, Greaves J, Martin KJ, Anderson KI, Brown P, Lilla S, Neilson MP, Tafelmeyer P, Zanivan S, Ismail S, Bryant DM, Tomkinson NCO, Chamberlain LH, Mastick GS, Insall RH, Machesky LM. Fam49/CYRI interacts with Rac1 and locally suppresses protrusions. Nat Cell Biol 20(10):1159-1171, 2018. e-Pub 2018. PMID: 30250061.
      55. Dandoulaki M, Petsalaki E, Sumpton D, Zanivan S, Zachos G. Src activation by Chk1 promotes actin patch formation and prevents chromatin bridge breakage in cytokinesis. J Cell Biol 217(9):3071-3089, 2018. e-Pub 2018. PMID: 29954829.
      56. Port J, Muthalagu N, Raja M, Ceteci F, Monteverde T, Kruspig B, Hedley A, Kalna G, Lilla S, Neilson L, Brucoli M, Gyuraszova K, Tait-Mulder J, Mezna M, Svambaryte S, Bryson A, Sumpton D, McVie A, Nixon C, Drysdale M, Esumi H, Murray GI, Sansom OJ, Zanivan SR, Murphy DJ. Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress. Cancer Discov 8(5):632-647, 2018. e-Pub 2018. PMID: 29500295.
      57. van der Reest J, Lilla S, Zheng L, Zanivan S, Gottlieb E. Proteome-wide analysis of cysteine oxidation reveals metabolic sensitivity to redox stress. Nat Commun 9(1):1581, 2018. e-Pub 2018. PMID: 29679077.
      58. Kugeratski FG, Batista M, Lima CVP, Neilson LJ, da Cunha ES, de Godoy LM, Zanivan S, Krieger MA, Marchini FK. Mitogen-Activated Protein Kinase Kinase 5 Regulates Proliferation and Biosynthetic Processes in Procyclic Forms of Trypanosoma brucei. J Proteome Res 17(1):108-118, 2018. e-Pub 2018. PMID: 29043805.
      59. van den Eshof BL, Hoogendijk AJ, Simpson PJ, van Alphen FPJ, Zanivan S, Mertens K, Meijer AB, van den Biggelaar M. Paradigm of Biased PAR1 (Protease-Activated Receptor-1) Activation and Inhibition in Endothelial Cells Dissected by Phosphoproteomics. Arterioscler Thromb Vasc Biol 37(10):1891-1902, 2017. e-Pub 2017. PMID: 28818855.
      60. Reid SE, Kay EJ, Neilson LJ, Henze AT, Serneels J, McGhee EJ, Dhayade S, Nixon C, Mackey JB, Santi A, Swaminathan K, Athineos D, Papalazarou V, Patella F, Roman-Fernandez A, ElMaghloob Y, Hernandez-Fernaud JR, Adams RH, Ismail S, Bryant DM, Salmeron-Sanchez M, Machesky LM, Carlin LM, Blyth K, Mazzone M, Zanivan S. Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium. EMBO J 36(16):2373-2389, 2017. e-Pub 2017. PMID: 28694244.
      61. Hernandez-Fernaud JR, Ruengeler E, Casazza A, Neilson LJ, Pulleine E, Santi A, Ismail S, Lilla S, Dhayade S, MacPherson IR, McNeish I, Ennis D, Ali H, Kugeratski FG, Al Khamici H, van den Biggelaar M, van den Berghe PV, Cloix C, McDonald L, Millan D, Hoyle A, Kuchnio A, Carmeliet P, Valenzuela SM, Blyth K, Yin H, Mazzone M, Norman JC, Zanivan S. Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nat Commun 8:14206, 2017. e-Pub 2017. PMID: 28198360.
      62. Diaz-Vera J, Palmer S, Hernandez-Fernaud JR, Dornier E, Mitchell LE, Macpherson I, Edwards J, Zanivan S, Norman JC. A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. J Cell Sci 130(4):697-711, 2017. e-Pub 2017. PMID: 28062852.
      63. Patella F, Neilson LJ, Athineos D, Erami Z, Anderson KI, Blyth K, Ryan KM, Zanivan S. In-Depth Proteomics Identifies a Role for Autophagy in Controlling Reactive Oxygen Species Mediated Endothelial Permeability. J Proteome Res 15(7):2187-97, 2016. e-Pub 2016. PMID: 27246970.
      64. Clarke CJ, Berg TJ, Birch J, Ennis D, Mitchell L, Cloix C, Campbell A, Sumpton D, Nixon C, Campbell K, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, Jones JL, Haywood L, Pulleine E, Yin H, Strathdee D, Sansom O, Blyth K, McNeish I, Zanivan S, Reynolds AR, Norman JC. The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis. Curr Biol 26(6):755-65, 2016. e-Pub 2016. PMID: 26948875.
      65. Deschoemaeker S, Di Conza G, Lilla S, Martin-Perez R, Mennerich D, Boon L, Hendrikx S, Maddocks OD, Marx C, Radhakrishnan P, Prenen H, Schneider M, Myllyharju J, Kietzmann T, Vousden KH, Zanivan S, Mazzone M. PHD1 regulates p53-mediated colorectal cancer chemoresistance. EMBO Mol Med 7(10):1350-65, 2015. e-Pub 2015. PMID: 26290450.
      66. Kuchnio A, Moens S, Bruning U, Kuchnio K, Cruys B, Thienpont B, Broux M, Ungureanu AA, Leite de Oliveira R, Bruyere F, Cuervo H, Manderveld A, Carton A, Hernandez-Fernaud JR, Zanivan S, Bartic C, Foidart JM, Noel A, Vinckier S, Lambrechts D, Dewerchin M, Mazzone M, Carmeliet P. The Cancer Cell Oxygen Sensor PHD2 Promotes Metastasis via Activation of Cancer-Associated Fibroblasts. Cell Rep 12(6):992-1005, 2015. e-Pub 2015. PMID: 26235614.
      67. Patella F, Schug ZT, Persi E, Neilson LJ, Erami Z, Avanzato D, Maione F, Hernandez-Fernaud JR, Mackay G, Zheng L, Reid S, Frezza C, Giraudo E, Fiorio Pla A, Anderson K, Ruppin E, Gottlieb E, Zanivan S. Proteomics-based metabolic modeling reveals that fatty acid oxidation (FAO) controls endothelial cell (EC) permeability. Mol Cell Proteomics 14(3):621-34, 2015. e-Pub 2015. PMID: 25573745.
      68. Guo Z, Neilson LJ, Zhong H, Murray PS, Zanivan S, Zaidel-Bar R. E-cadherin interactome complexity and robustness resolved by quantitative proteomics. Sci Signal 7(354):rs7, 2014. e-Pub 2014. PMID: 25468996.
      69. van den Biggelaar M, Hernandez-Fernaud JR, van den Eshof BL, Neilson LJ, Meijer AB, Mertens K, Zanivan S. Quantitative phosphoproteomics unveils temporal dynamics of thrombin signaling in human endothelial cells. Blood 123(12):e22-36, 2014. e-Pub 2014. PMID: 24501219.
      70. Reid S, Hernandez-Fernaud JR, Zanivan S. In vivo quantitative proteomics for the study of oncometabolism. Methods Enzymol 543:235-59, 2014. e-Pub 2014. PMID: 24924136.
      71. Zanivan S, Maione F, Hein MY, Hernandez-Fernaud JR, Ostasiewicz P, Giraudo E, Mann M. SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers. Mol Cell Proteomics 12(12):3599-611, 2013. e-Pub 2013. PMID: 23979707.
      72. Neuhauser N, Nagaraj N, McHardy P, Zanivan S, Scheltema R, Cox J, Mann M. High performance computational analysis of large-scale proteome data sets to assess incremental contribution to coverage of the human genome. J Proteome Res 12(6):2858-68, 2013. e-Pub 2013. PMID: 23611042.
      73. Schiller HB, Hermann MR, Polleux J, Vignaud T, Zanivan S, Friedel CC, Sun Z, Raducanu A, Gottschalk KE, Thery M, Mann M, Fassler R. beta1- and alphav-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectin-based microenvironments. Nat Cell Biol 15(6):625-36, 2013. e-Pub 2013. PMID: 23708002.
      74. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, Nixon C, Karim SA, Caswell PT, Noll JE, Coffill CR, Lane DP, Sansom OJ, Neilsen PM, Norman JC, Vousden KH. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 32(10):1252-65, 2013. e-Pub 2013. PMID: 22580601.
      75. Zanivan S, Meves A, Behrendt K, Schoof EM, Neilson LJ, Cox J, Tang HR, Kalna G, van Ree JH, van Deursen JM, Trempus CS, Machesky LM, Linding R, Wickstrom SA, Fassler R, Mann M. In vivo SILAC-based proteomics reveals phosphoproteome changes during mouse skin carcinogenesis. Cell Rep 3(2):552-66, 2013. e-Pub 2013. PMID: 23375375.
      76. Azimifar SB, Bottcher RT, Zanivan S, Grashoff C, Kruger M, Legate KR, Mann M, Fassler R. Induction of membrane circular dorsal ruffles requires co-signalling of integrin-ILK-complex and EGF receptor. J Cell Sci 125(Pt 2):435-48, 2012. e-Pub 2012. PMID: 22357970.
      77. Zanivan S, Krueger M, Mann M. In vivo quantitative proteomics: the SILAC mouse. Methods Mol Biol 757:435-50, 2012. e-Pub 2012. PMID: 21909926.
      78. Meves A, Geiger T, Zanivan S, DiGiovanni J, Mann M, Fassler R. Beta1 integrin cytoplasmic tyrosines promote skin tumorigenesis independent of their phosphorylation. Proc Natl Acad Sci U S A 108(37):15213-8, 2011. e-Pub 2011. PMID: 21876123.
      79. Kruger M, Moser M, Ussar S, Thievessen I, Luber CA, Forner F, Schmidt S, Zanivan S, Fassler R, Mann M. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 134(2):353-64, 2008. e-Pub 2008. PMID: 18662549.
      80. Zanivan S, Corà D, Caselle M, Bussolino F. VRG: A database of vascular dysfunctions related genes. Computers & Mathematics with Applications 55(5):1068-1073, 2008.
      81. Zanivan S, Cascone I, Peyron C, Molineris I, Marchio S, Caselle M, Bussolino F. A new computational approach to analyze human protein complexes and predict novel protein interactions. Genome Biol 8(12):R256, 2007. e-Pub 2007. PMID: 18053208.
      82. Parsons-Wingerter P, Kasman IM, Norberg S, Magnussen A, Zanivan S, Rissone A, Baluk P, Favre CJ, Jeffry U, Murray R, McDonald DM. Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am J Pathol 167(1):193-211, 2005. e-Pub 2005. PMID: 15972964.
      83. Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, Zammataro L, Primo L, Tamagnone L, Logan M, Tessier-Lavigne M, Taniguchi M, Puschel AW, Bussolino F. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424(6947):391-7, 2003. e-Pub 2003. PMID: 12879061.

      Invited Articles

      1. Kay EJ, Zanivan S. Bicarbonate transport as regulator of antitumour immunity in pancreatic cancer. Mol Oncol 17(4):541-544, 2023. e-Pub 2023. PMID: 36807529.
      2. Kay EJ, Zanivan S. Methylmalonic acid: an age-related metabolite that drives tumour aggressiveness. Nat Metab 4(4):412-413, 2022. e-Pub 2022. PMID: 35361957.
      3. Kay EJ, Zanivan S. Two opposing sub-populations of fibroblasts decide progression of pancreatic cancer. Cancer Cell 39(9):1175-1177, 2021. e-Pub 2021. PMID: 34520729.
      4. Reid SE, Zanivan S. Tumor stiffness extends its grip on the metastatic microenvironment. Mol Cell Oncol 4(6):e1372866, 2017. e-Pub 2017. PMID: 29209654.
      5. Norman J, Zanivan S. Chloride intracellular channel 3: A secreted pro-invasive oxidoreductase. Cell Cycle 16(21):1993-1994, 2017. e-Pub 2017. PMID: 28933594.

      Review Articles

      1. Grande Kugeratski, F, Kay, E, Zanivan, SR. Cancer-associated fibroblasts as mediators of tissue microenvironment remodeling in cancer. Current Opinion in Cell Biology 96, 2025. e-Pub 2025. PMID: 40663954.
      2. Kay, E, Zanivan, SR. The tumor microenvironment is an ecosystem sustained by metabolic interactions. Cell Reports 44(3), 2025. e-Pub 2025. PMID: 40088447.
      3. Kay EJ, Zanivan S, Rufini A. Proline metabolism shapes the tumor microenvironment: from collagen deposition to immune evasion. Curr Opin Biotechnol 84:103011, 2023. e-Pub 2023. PMID: 37864905.
      4. Kugeratski FG, Santi A, Zanivan S. Extracellular vesicles as central regulators of blood vessel function in cancer. Sci Signal 15(753):eaaz4742, 2022. e-Pub 2022. PMID: 36166511.
      5. Kay EJ, Zanivan S. Metabolic pathways fuelling protumourigenic cancer-associated fibroblast functions. Current Opinion in Systems Biology 28:100377, 2021.
      6. Paterson K, Zanivan S, Glasspool R, Coffelt SB, Zagnoni M. Microfluidic technologies for immunotherapy studies on solid tumours. Lab Chip 21(12):2306-2329, 2021. e-Pub 2021. PMID: 34085677.
      7. Domen A, Quatannens D, Zanivan S, Deben C, Van Audenaerde J, Smits E, Wouters A, Lardon F, Roeyen G, Verhoeven Y, Janssens A, Vandamme T, van Dam P, Peeters M, Prenen H. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers (Basel) 13(5), 2021. e-Pub 2021. PMID: 33673405.
      8. Kay EJ, Koulouras G, Zanivan S. Regulation of Extracellular Matrix Production in Activated Fibroblasts: Roles of Amino Acid Metabolism in Collagen Synthesis. Front Oncol 11:719922, 2021. e-Pub 2021. PMID: 34513697.
      9. Santi A, Kugeratski FG, Zanivan S. Cancer Associated Fibroblasts: The Architects of Stroma Remodeling. Proteomics 18(5-6):e1700167, 2018. e-Pub 2018. PMID: 29280568.
      10. Hernandez-Fernaud JR, Reid SE, Neilson LJ, Zanivan S. Quantitative mass spectrometry-based proteomics in angiogenesis. Proteomics Clin Appl 7(7-8):464-76, 2013. e-Pub 2013. PMID: 23161605.

      Other Articles

      1. Serini, G, Valdembri, D, Zanivan, SR, Morterra, G, Burkhardt, C, Caccavari, F, Zammataro, L, Primo, L, Tamagnone, L, Logan, M, Tessier-Lavigne, M, Taniguchi, M, Püschel, AW, Bussolino, F Erratum to. Nature 627(8002):E7, 2024. PMID: 38383792.
      2. Kay, E, Paterson, K, Riera-Domingo, C, Sumpton, D, Däbritz, JM, Tardito, S, Boldrini, C, Hernandez-Fernaud, JR, Athineos, D, Dhayade, S, Stepanova, E, Gjerga, E, Neilson, LJ, Lilla, S, Hedley, A, Koulouras, G, McGregor, G, Jamieson, C, Johnson, RM, Park, M, Kirschner, K, Miller, CJ, Kamphorst, JJ, Loayza-Puch, F, Saez-Rodriguez, J, Mazzone, M, Blyth, K, Zagnoni, M, Zanivan, SR Author Correction. Nature Metabolism 4(8):1084, 2022. PMID: 35927357.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Zanivan Laboratory

      • Experimental Therapeutics department

      • Cancer Medicine division

      • Proteomics Core Facility

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top